Exact Sciences has begun enrolling patients in its Multi-Cancer Early Detection (MCED) Falcon Registry study, aimed at evaluating the clinical performance and impact of its MCED test. The study will involve up to 25,000 patients across multiple sites, including Baylor Scott & White and Endeavor Health, to assess early cancer detection’s effectiveness and its potential to transform cancer care. The data gathered will support the test’s future development and regulatory discussions, aligning with the broader goal of reducing cancer mortality.
Author: Abhay Panchal
The American College of Gastroenterology (ACG) and the American Society for Gastrointestinal Endoscopy (ASGE) have updated their quality indicators for colonoscopy, introducing three key updates. These include new benchmarks for adenoma detection rates, the importance of patient follow-up after colonoscopy, and enhanced guidelines for the documentation of colonoscopy outcomes. These updates aim to improve the effectiveness and safety of colonoscopy procedures.
A panel of 24 international experts developed 19 consensus statements to guide clinicians in referring patients with large nonpedunculated colorectal polyps for resection. These guidelines focus on critical factors like polyp location, size, and histopathology, as well as patient demographics and previous endoscopy findings. The aim is to improve the triage and planning of endoscopic resection techniques, ultimately reducing colorectal cancer incidence and improving patient outcomes. High-quality photodocumentation was also emphasized as essential for accurate lesion assessment.
The FDA has approved Gilead Sciences’ drug Livdelzi (bulevirtide) for the treatment of primary biliary cholangitis (PBC), a chronic liver disease. Livdelzi is the first and only approved treatment specifically targeting patients with PBC who are inadequate responders to ursodeoxycholic acid (UDCA), the standard treatment. This approval provides a new option for patients with limited treatment alternatives, potentially improving outcomes for those with this challenging condition.
Johns Hopkins Kimmel Cancer Center has developed Esopredict, a PCR-based test that helps predict the progression of Barrett’s esophagus to esophageal cancer. By analyzing DNA methylation in specific genes, Esopredict identifies patients at higher risk, enabling personalized monitoring and treatment strategies. The test has shown that patients in the highest risk group are 15.2 times more likely to develop high-grade dysplasia or esophageal cancer. This tool aims to improve early detection and reduce unnecessary procedures.
Dr. Ishwari Prasad, a Tampa gastroenterologist, was placed on probation by the Florida Board of Medicine for serious lapses during two colonoscopies, including allowing an unlicensed surgical tech to handle scope insertion and failing to halt a procedure despite a patient’s screams due to insufficient sedation. Prasad, who has faced prior malpractice claims, must undergo evaluation and supervised procedures before resuming solo gastroenterology work.
The article discusses the growing role of AI, computer vision, and machine learning in surgery, emphasizing how these technologies are enhancing precision, operational efficiency, and patient outcomes. Despite challenges like data privacy, resistance to change, and ethical concerns, AI’s potential in surgery is vast, from real-time tool tracking to predictive analytics for optimizing operations. The future looks promising as AI continues to evolve, paving the way for improved healthcare practices and outcomes.
A trial led by Newcastle University and South Tyneside and Sunderland NHS Foundation Trust demonstrated that AI significantly improves colonoscopy effectiveness in detecting precancerous polyps. The GI Genius AI device, integrated into traditional colonoscopy technology, identified abnormalities that could be missed by the human eye. The trial, involving 2,032 patients, showed that AI could help prevent bowel cancer by detecting and removing potential cancerous lesions earlier. This technology is expected to be adopted more widely to enhance early cancer detection.
Aasma Shaukat, MD, MPH discusses the challenges of low colorectal cancer (CRC) screening rates in the U.S., despite the availability of effective methods like colonoscopy and stool-based tests. She highlights the recent FDA approval of a blood test for CRC screening, which may boost adherence due to its simplicity. However, there are concerns about its efficacy compared to traditional methods and its potential impact on existing screening practices. The article urges clinicians to consider the role of this new test in their practice.
DayTwo, a personalized microbiome health company, has shut down operations. The company, which specialized in using microbiome data to provide personalized dietary recommendations, faced challenges despite its innovative approach to managing conditions like diabetes. This closure highlights the difficulties in the personalized health sector, especially for startups relying on cutting-edge but complex technologies.